Latest Kaiser Health News Stories
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
Doctors and patients say they’re compelled to use off-label meds as research goes unfunded.
For one patient, a three-month supply of insulin is $3,700 in the U.S. versus $600 in Mexico. But is it legal?
Sen. Mike Enzi said he knew of a foundation that would import insulin for patients, but it doesn’t appear to exist.
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
Democratic governors and mayors are unveiling new ideas to control costs and expand coverage. The federal government shutdown has spared most health agencies, but not all. And learn the latest on that lawsuit out of Texas, which is threatening the Affordable Care Act once again. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN’s Jordan Rau about the latest “Bill of the Month.”
The price of insulin keeps going up. For people with Type 1 diabetes, high prices can be a life-or-death issue. Now a grass-roots movement is pushing for change.
Insurance companies profit from government contracts but are subject to little oversight of how they spend the money or care for patients. The expansion of Medicaid under the Affordable Care Act has only exacerbated the problem.
A DaVita subsidiary will pay $270 million over allegations that it cheated the federal government for years.
Alec Raeshawn Smith was 23 when diagnosed with Type 1 diabetes, and 26 when he died. He couldn’t afford $1,300 per month for his insulin and other diabetes supplies. So he tried to stretch the doses.
The number of diabetes drug prescriptions filled for low-income people enrolled in Medicaid rose sharply in states that expanded eligibility for the program under the Affordable Care Act, according to a new study.
The vaccine, BCG, is relatively cheap. But experts caution the therapy could be overhyped and, if proven effective, wind up overpriced.
In a major coup for the beverage industry, California lawmakers agreed to ban cities and counties from adopting soda taxes for the next 12 years. In exchange, the beverage industry agreed to pull an initiative off the November ballot that, if passed, would have made it much harder for local governments to raise taxes.
A small group of insurers offers some members with serious illnesses medically tailored meals to improve their health.
Self-management classes can help the tens of millions of Americans now diagnosed with Type 2 diabetes. But the education can come with a high price tag.
On April 1, Medicare launched a major initiative — a diabetes prevention program for seniors and people with serious disabilities— that is available in only a few cities.
A Bay Area public health campaign harnesses the power of poetry to confront the root causes of a diabetes epidemic that is disproportionately hitting minority youth and those from low-income homes.
Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR’s Weekend Edition. Listen to the broadcast and read a transcript of that conversation.
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
From infections linked to the storm to trying to treat people with chronic diseases in damaged clinics, health officials on this American territory struggle to stay ahead of the needs.